CY1106078T1 - Χρηση ενισχυτη προσληψης γλυκοζης για τη μειωση μεθ-ισχαιμικης βλαβης της καρδιας - Google Patents

Χρηση ενισχυτη προσληψης γλυκοζης για τη μειωση μεθ-ισχαιμικης βλαβης της καρδιας

Info

Publication number
CY1106078T1
CY1106078T1 CY20061100616T CY061100616T CY1106078T1 CY 1106078 T1 CY1106078 T1 CY 1106078T1 CY 20061100616 T CY20061100616 T CY 20061100616T CY 061100616 T CY061100616 T CY 061100616T CY 1106078 T1 CY1106078 T1 CY 1106078T1
Authority
CY
Cyprus
Prior art keywords
glucose uptake
ischemic heart
uptake enhancer
reduce post
heart damage
Prior art date
Application number
CY20061100616T
Other languages
English (en)
Inventor
Antoine Michel A. Bril
Robin Edwin Buckingham
Nassirah Khandoudi
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of CY1106078T1 publication Critical patent/CY1106078T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Μία μέθοδος για τη μείωση μεθ-ισχαιμικής βλάβης της καρδιάς και/ή βελτίωση της λειτουργικής αποκατάσταση της καρδιάς μετά από ισχαιμία του μυοκαρδίου η οποία μέθοδος περιλαμβάνει τη χορήγηση μίας αποτελεσματικής, όχι-τοξικής ποσότητας ενός ενισχυτή πρόσληψης γλυκόζης σε ένα ανθρώπινο ή όχι-ανθρώπινο θηλαστικό που τη χρειάζεται.
CY20061100616T 1998-07-21 2006-05-12 Χρηση ενισχυτη προσληψης γλυκοζης για τη μειωση μεθ-ισχαιμικης βλαβης της καρδιας CY1106078T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
PCT/GB1999/002358 WO2000004889A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart

Publications (1)

Publication Number Publication Date
CY1106078T1 true CY1106078T1 (el) 2011-06-08

Family

ID=26314086

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100616T CY1106078T1 (el) 1998-07-21 2006-05-12 Χρηση ενισχυτη προσληψης γλυκοζης για τη μειωση μεθ-ισχαιμικης βλαβης της καρδιας

Country Status (35)

Country Link
EP (2) EP1523980A3 (el)
JP (1) JP2002521325A (el)
KR (1) KR20010079550A (el)
CN (1) CN1167416C (el)
AP (1) AP1416A (el)
AR (1) AR020614A1 (el)
AT (1) ATE318588T1 (el)
AU (1) AU5053599A (el)
BG (1) BG105251A (el)
BR (1) BR9912144A (el)
CA (1) CA2338216A1 (el)
CO (1) CO5060465A1 (el)
CY (1) CY1106078T1 (el)
CZ (1) CZ2001250A3 (el)
DE (1) DE69930125T2 (el)
DK (1) DK1098638T3 (el)
DZ (1) DZ2854A1 (el)
EA (1) EA004772B1 (el)
ES (1) ES2259839T3 (el)
GC (1) GC0000173A (el)
HU (1) HUP0103870A3 (el)
ID (1) ID27850A (el)
IL (1) IL140741A0 (el)
MA (1) MA26662A1 (el)
NO (1) NO20010293L (el)
NZ (1) NZ509175A (el)
OA (1) OA11583A (el)
PE (1) PE20000881A1 (el)
PL (1) PL345663A1 (el)
PT (1) PT1098638E (el)
SI (1) SI1098638T1 (el)
SK (1) SK1022001A3 (el)
TR (1) TR200100208T2 (el)
TW (2) TWI239836B (el)
WO (1) WO2000004889A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2204684T3 (es) * 1999-08-27 2004-05-01 Eli Lilly And Company Derivados de biaril-oxa(tia)zol y su uso como modulares de ppar.
YU1203A (sh) * 2000-06-16 2006-05-25 Smithkline Beecham P.L.C. Lečenje i prevencija stanja vezanih za insulinsku rezistenciju srca
AU2002319677B8 (en) 2001-07-23 2009-04-30 Atwater Management Llc Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
HUP0002941A3 (en) * 1996-09-12 2001-11-28 Sankyo Company Ltd Chuo Ku Glutathione reductase activity potentiator containing troglitazone
WO1999025346A1 (en) * 1997-11-19 1999-05-27 Takeda Chemical Industries, Ltd. Novel apoptosis inhibitors
WO1999043326A1 (en) * 1998-02-24 1999-09-02 The Trustees Of The University Of Pennsylvania Use of a cardiac purinoceptor to effect cellular glucose uptake
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
BG105251A (en) 2001-10-31
NO20010293D0 (no) 2001-01-18
EA200100164A1 (ru) 2001-08-27
KR20010079550A (ko) 2001-08-22
EA004772B1 (ru) 2004-08-26
DE69930125D1 (de) 2006-04-27
NO20010293L (no) 2001-03-07
SI1098638T1 (sl) 2006-06-30
EP1523980A2 (en) 2005-04-20
EP1523980A3 (en) 2009-03-18
AP1416A (en) 2005-06-13
NZ509175A (en) 2003-10-31
TW200307532A (en) 2003-12-16
WO2000004889A1 (en) 2000-02-03
ID27850A (id) 2001-04-26
MA26662A1 (fr) 2004-12-20
CZ2001250A3 (cs) 2002-03-13
CN1167416C (zh) 2004-09-22
CA2338216A1 (en) 2000-02-03
BR9912144A (pt) 2001-04-03
AR020614A1 (es) 2002-05-22
AU5053599A (en) 2000-02-14
TWI239836B (en) 2005-09-21
OA11583A (en) 2004-07-01
HUP0103870A2 (hu) 2002-05-29
HUP0103870A3 (en) 2003-06-30
EP1098638A1 (en) 2001-05-16
ATE318588T1 (de) 2006-03-15
CN1310619A (zh) 2001-08-29
TR200100208T2 (tr) 2001-05-21
AP2001002033A0 (en) 2001-03-31
EP1098638B1 (en) 2006-03-01
GC0000173A (en) 2006-03-29
JP2002521325A (ja) 2002-07-16
IL140741A0 (en) 2002-02-10
SK1022001A3 (en) 2001-08-06
PL345663A1 (en) 2002-01-02
DZ2854A1 (fr) 2003-12-01
PT1098638E (pt) 2006-07-31
ES2259839T3 (es) 2006-10-16
DE69930125T2 (de) 2006-10-05
DK1098638T3 (da) 2006-06-19
CO5060465A1 (es) 2001-07-30
PE20000881A1 (es) 2000-10-07

Similar Documents

Publication Publication Date Title
CY1118738T1 (el) Χρηση της ινσουλινης γλαργινη για τη μειωση ή την προληψη της καρδιαγγειακης νοσηροτητας και θνησιμοτητας σε προδιαβητικους ασθενεις
BRPI0411677A (pt) métodos de uso de compostos heterocìclicos [3.2.0] e seus análogos
CY1118429T1 (el) Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
EA200300628A1 (ru) Соединения, специфические к аденозиновому a, aи aрецептору, и их применение
TR199902033T2 (xx) Diyabet i�in s�lfonilura-glitazon sinerjik kombinasyonlar�.
DE69800355D1 (de) Pulsfrequenz- und Herzfrequenz-Übereinstimmungsdetektion für die Pulsoxymetrie
EA200101089A1 (ru) Новый способ лечения
EA200100573A1 (ru) Применение ингибитора циклооксигеназы-2, ингибитора матричной металлопротеиназы, противоопухолевого лекарственного средства и факультативно облучения в качестве комбинированного способа лечения неоплазии
ATE411831T1 (de) Mehrfach-signalmuster zum filtern von fernfeld-r- zacken
CY1106046T1 (el) Μεθοδος για την θεραπευτικη αγωγη ινωσεως με χρησιμοποιηση ενος ανταγωνιστου της αλφα-4-υπομοναδος της ιντεγκρινης
MA26804A1 (fr) Acides 3-propyl-gamma-aminobutyriques mono- et disubstitues.
CY1104971T1 (el) Παρασκευασμα αποϊνιδοτιδιου και g-csf και η χρηση του για να κινητοποιει αιμοποιητικους προγονους
DE60105989D1 (de) Implantierbarer herzstimulator
ATE317693T1 (de) Substituierte stilbene mit gefässschädigender aktivität
CY1106078T1 (el) Χρηση ενισχυτη προσληψης γλυκοζης για τη μειωση μεθ-ισχαιμικης βλαβης της καρδιας
DK1294379T3 (da) En hidtil ukendt anvendelse af deferipron
DE69929192D1 (de) Herzstimulator mit bestimmung des stimulationsschwellwertes
CR5352A (es) Cepillo para retencion mejorada de cerdas y enclaje de alambre del mismo
DE69707163D1 (de) Klebstoffe, beständig gegen Hautpenetrationsförderer
DE60144383D1 (de) Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten
FI902321A0 (fi) Butensyraderivat.
NL1016213A1 (nl) Hartpacing samenstel met verbeterde fysiologische gebeurtenis classificatie en hartbewaking gebaseerd op DSP.
BR0114604A (pt) Tratamento de c‰nceres
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários